PharVision Advisers’s Capital One COF Stock Holding History

PharVision Advisers’s Portfolio COF Stock Details COF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-923	Closed	-$224K	–	220
2025 Q4	$224K	Buy	+923	New	+$205K	0.11%	464

Other funds holding COF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

PharVision Advisers's COF Position: Q1 2026 in Review

PharVision Advisers sold out of Capital One (COF) in Q1 2026, closing a stake of 923 shares — an estimated $224K sold.

PharVision Advisers first reported a position in COF in Q4 2025 and held it in 1 quarter. The position peaked at $224K in Q4 2025. 2,063 funds tracked by Wall St. Rank hold COF as of Q1 2026.

PharVision Advisers reported no remaining Capital One position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 923 Capital One shares in Q1 2026, an estimated $224K.
PharVision Advisers first reported a position in Capital One in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Capital One position peaked at $224K in Q4 2025.
2,063 funds tracked by Wall St. Rank held Capital One as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.